180 related articles for article (PubMed ID: 18366253)
1. The potential effect of statins on rituximab immunotherapy.
Cragg MS
PLoS Med; 2008 Mar; 5(3):e77. PubMed ID: 18366253
[TBL] [Abstract][Full Text] [Related]
2. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.
Winiarska M; Bil J; Wilczek E; Wilczynski GM; Lekka M; Engelberts PJ; Mackus WJ; Gorska E; Bojarski L; Stoklosa T; Nowis D; Kurzaj Z; Makowski M; Glodkowska E; Issat T; Mrowka P; Lasek W; Dabrowska-Iwanicka A; Basak GW; Wasik M; Warzocha K; Sinski M; Gaciong Z; Jakobisiak M; Parren PW; Golab J
PLoS Med; 2008 Mar; 5(3):e64. PubMed ID: 18366248
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
4. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
Anderson DR; Grillo-López A; Varns C; Chambers KS; Hanna N
Biochem Soc Trans; 1997 May; 25(2):705-8. PubMed ID: 9191187
[No Abstract] [Full Text] [Related]
5. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D
Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody therapy and non-Hodgkin's lymphoma.
Goldstein MR; Mascitelli L; Pezzetta F
N Engl J Med; 2009 Jan; 360(2):192; author reply 193. PubMed ID: 19129537
[No Abstract] [Full Text] [Related]
7. Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab.
Dillman RO
Semin Oncol; 2003 Aug; 30(4):434-47. PubMed ID: 12939712
[TBL] [Abstract][Full Text] [Related]
8. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
[TBL] [Abstract][Full Text] [Related]
9. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.
Kohrt HE; Sagiv-Barfi I; Rafiq S; Herman SE; Butchar JP; Cheney C; Zhang X; Buggy JJ; Muthusamy N; Levy R; Johnson AJ; Byrd JC
Blood; 2014 Mar; 123(12):1957-60. PubMed ID: 24652965
[No Abstract] [Full Text] [Related]
11. [Interleukin-2 improves the antitumor activity of Rituximab in patients with B-cell lymphoma in vitro].
Zhang WX; Guo J; Lin BH; Meng SN; Wang XP; Xie Y; Zheng W; Zhang YT; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):41-4. PubMed ID: 17649726
[TBL] [Abstract][Full Text] [Related]
12. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
Weng WK; Levy R
Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
[TBL] [Abstract][Full Text] [Related]
13. Rituximab not affected by statins?
Pharmacogenomics; 2009 Feb; 10(2):259. PubMed ID: 19207027
[No Abstract] [Full Text] [Related]
14. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
Ge X; Wu L; Hu W; Fernandes S; Wang C; Li X; Brown JR; Qin X
Clin Cancer Res; 2011 Nov; 17(21):6702-11. PubMed ID: 21918174
[TBL] [Abstract][Full Text] [Related]
15. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
[TBL] [Abstract][Full Text] [Related]
16. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
Harjunpää A; Junnikkala S; Meri S
Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
[TBL] [Abstract][Full Text] [Related]
17. [Malignant lymphoma. Current topics. 1. Antibody therapy].
Izutsu K
Nihon Naika Gakkai Zasshi; 2008 Jul; 97(7):1620-6. PubMed ID: 18720604
[No Abstract] [Full Text] [Related]
18. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
Ennishi D; Asai H; Maeda Y; Shinagawa K; Ikeda K; Yokoyama M; Terui Y; Takeuchi K; Yoshino T; Matsuo K; Hatake K; Tanimoto M
Ann Oncol; 2010 Jun; 21(6):1217-1221. PubMed ID: 19884246
[TBL] [Abstract][Full Text] [Related]
19. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
Buchner M; Brantner P; Stickel N; Prinz G; Burger M; Bär C; Dierks C; Pfeifer D; Ott A; Mertelsmann R; Gribben JG; Veelken H; Zirlik K
Br J Haematol; 2010 Oct; 151(2):167-78. PubMed ID: 20738306
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond.
Bello C; Sotomayor EM
Hematology Am Soc Hematol Educ Program; 2007; ():233-42. PubMed ID: 18024635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
